Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).
In the trial, the dose escalation for dianhydrogalacitol has increased to 50mg with no major toxicities in patients with multiple recurrent GBM, explains Butowski.
Of the 5 patients treated at Butowski's institution, 3 are doing very well and tolerated multiple doses of the drug, he explains. The key to using dianhydrogalacitol effectively will focus on sequencing the agent with chemotherapy, Butowski believes.
<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting